Literature DB >> 29380702

Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.

Nevim Aygun1.   

Abstract

Neuroblastoma derived from primitive cells of the sympathetic nervous system typically develops in the adrenal medulla or paraspinal ganglia. Neuroblastoma usually occurs sporadically, but familial cases are also observed. ALK and PHOX2B germline mutations can cause hereditary neuroblastoma, while a common genetic variation in chromosome 6p22 is associated to sporadic neuroblastoma. However, the aetiology of sporadic neuroblastoma is not exactly known. This embryonic malignancy generally represents the second most common solid tumour after central nervous system tumours throughout the world in childhood. Neuroblastoma is a complex disease that has different clinical courses, from metastatic spread to spontaneous regression. Spontaneous regression can occur without therapy in primary or metastatic site. Potential regression mechanisms primarily involve apoptosis, hypermethylation of subtelomeric DNA, immune response and Nerve Growth Factor (NGF) deprivation. Neuroblastoma is a heterogeneous tumour that can show many different chromosomal abnormalities; e.g. MYCN amplification, 1p deletion, unbalanced translocations involving chromosome 17, aneuploidies and Loss of Heterozygosity (LOH) events. Tyrosine kinase receptors TrkA, TrkB and TrkC, their ligands NGF, Brain-derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3), and Aurora Kinase A (AURKA) play a regulatory role in differentiation, apoptosis, cell proliferation, tumourigenesis, angiogenesis or metastasis of neuroblastoma. TrkA expression is associated with differentiation or regression, depending on presence or absence of NGF, whereas TrkB and BDNF are mostly expressed in aggressive neuroblastomas with MYCN amplification. MYCN is amplified in 18-38% of neuroblastoma cases. MYCN amplification mechanism remains to be completely clarified. This paper reviews the biological/genetic features and their clinical importance in neuroblastoma. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Neuroblastoma; biological and genetic features; cell behaviour; cell signalling pathways; chromosomalzzm321990abnormalities; clinical behaviour; clinical importance; genomic signature.

Mesh:

Substances:

Year:  2018        PMID: 29380702     DOI: 10.2174/1573396314666180129101627

Source DB:  PubMed          Journal:  Curr Pediatr Rev        ISSN: 1573-3963


  23 in total

1.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

Review 2.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 3.  Recent clinical research on the application of liquid biopsy in neuroblastoma.

Authors:  Si-Yang Liu; Fei-Qiu Wen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-03-15

4.  Control of cell state transitions.

Authors:  Melinda Halasz; Nora Rauch; Oleksii S Rukhlenko; Vadim Zhernovkov; Thomas Prince; Kieran Wynne; Stephanie Maher; Eugene Kashdan; Kenneth MacLeod; Neil O Carragher; Walter Kolch; Boris N Kholodenko
Journal:  Nature       Date:  2022-09-14       Impact factor: 69.504

5.  Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.

Authors:  Kavitha Godugu; Ozlem O Karakus; Kazutoshi Fujioka; Gennadi V Glinsky; Shaker A Mousa
Journal:  J Cancer       Date:  2022-05-16       Impact factor: 4.478

6.  Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells.

Authors:  Etienne C Gozlan; Boris I Chobrutskiy; Saif Zaman; Michelle Yeagley; George Blanck
Journal:  J Mol Neurosci       Date:  2021-03-05       Impact factor: 3.444

Review 7.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

8.  NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma.

Authors:  Prasanna Kumar Juvvuna; Tanmoy Mondal; Mirco Di Marco; Subazini Thankaswamy Kosalai; Meena Kanduri; Chandrasekhar Kanduri
Journal:  Neurooncol Adv       Date:  2021-04-09

9.  MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.

Authors:  Nevim Aygun; Oguz Altungoz
Journal:  Mol Med Rep       Date:  2018-11-22       Impact factor: 2.952

10.  LINC00839 Regulates Proliferation, Migration, Invasion, Apoptosis and Glycolysis in Neuroblastoma Cells Through miR-338-3p/GLUT1 Axis.

Authors:  Lixia Yang; Liangyan Pei; Jilong Yi
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.